Ernexa Therapeutics (ERNAW) Non-Current Debt (2013 - 2023)

Ernexa Therapeutics has reported Non-Current Debt for 11 years, with the latest figure at $768000.0 in Q1 2023.

• For the quarter ending Q1 2023, Non-Current Debt changed N/A year-over-year to $768000.0; the trailing twelve-month figure through Mar 2023 stood at $768000.0 (changed N/A YoY), and the FY2022 full-year result was $1.2 million, changed N/A from the prior year.
• Non-Current Debt for Q1 2023 stood at $768000.0, down from $1.2 million in the prior quarter.
• The five-year high for Non-Current Debt was $2.5 million in Q1 2019, with the low at $77670.0 in Q1 2021.
• Historically, Non-Current Debt has averaged $1.3 million across 5 years, with a median of $1.4 million in 2020.
• Annual changes were most pronounced in 2019 — Non-Current Debt declined 10.96% — and 2020, when it dropped 18.22%.
• Ernexa Therapeutics' Non-Current Debt stood at $2.0 million in 2019, then sank by 90.24% to $194000.0 in 2020, then plunged by 59.96% to $77670.0 in 2021, then surged by 1452.72% to $1.2 million in 2022, then plunged by 36.32% to $768000.0 in 2023.
• The last three Non-Current Debt figures came in at $768000.0 (Q1 2023), $1.2 million (Q4 2022), and $77670.0 (Q1 2021), per Business Quant data.